REG - Physiomics PLC - DoseMeRx Update

PhysiomicsAnnouncement

21/02/2022 10:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220221:nRSU2768Ca&default-theme=true

RNS Number : 2768C  Physiomics PLC  21 February 2022

21 February 2022

Physiomics plc

("Physiomics" or "the Company")

 

DoseMeRx Update

 

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions, would like to provide an update on its collaboration with
Tabula Rasa Healthcare Inc ("TRHC") in the field of oncology (first announced
in December 2020) following THRC's recent press release regarding the intended
sale of its DoseMeRx solution.

Physiomics' personalised dosing application for docetaxel in prostate cancer
was successfully integrated into the DoseMeRx platform over the course of
2021. Following positive feedback on this proof of concept implementation,
Physiomics and DoseMeRx are exploring further development in other cancer
indications that may offer more significant commercial potential.  During the
sale process announced by TRHC, Physiomics continues to work with DoseMeRx and
looks forward to further developing the collaboration with DoseMeRx's new
owners as and when the transaction is completed.

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0)20 3764 2341

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions. The Company's Virtual Tumour™ technology uses computer
modelling to predict the effects of cancer drugs and treatments to improve the
success rate of drug discovery and development projects while reducing time
and cost. The predictive capability of Physiomics' technologies have been
confirmed by over 90 projects, involving over 40 targets and 70 drugs, and has
worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle
Therapeutics.

For more information please visit:

 

www.physiomics.co.uk (http://www.physiomics.co.uk)

www.twitter.com/Physiomics (http://www.twitter.com/Physiomics)

www.linkedin.com/company/physiomics-plc/
(http://www.linkedin.com/company/physiomics-plc/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEANAFASLAEEA